Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences

Kim, Taylor Olmsted; Grimes, Amanda; Kirk, Susan E.; Gilbert, Megan; Reed, Helen; Staggers, Kristen A.; Walker, Lauryn A; Arulselvan, Abinaya; Cohen, Arthur A.; Lambert, Michele P.; Despotovic, Jenny M.

doi:10.1182/blood.2020004888

Cited by 9 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of ITP in children is up to two times higher in the spring than in the summer, possibly reflecting the higher incidence of viral infections in the spring. The incidence of ITP is significantly lower in African-Americans than in Europeans Therefore, blacks with thrombocytopenia should be carefully evaluated to confirm ITP and not another type of thrombocytopenia [6]. ITP appears to be as common in the Asia-Pacific region as in Europe.…”

Section: Epidemiologymentioning

confidence: 99%

Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland

Matzdorff¹,

Alesci²,

Gebhart³

et al. 2023

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

Section: Epidemiologymentioning

confidence: 99%

Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland

Matzdorff¹,

Alesci²,

Gebhart³

et al. 2023

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Notably, there was a difference in the ranking of reasons for starting second‐line treatment between White and non‐White patients. A recent study of children with chronic ITP suggested that these two populations may have distinct ITP courses 21 . Given this emerging data about the association of race and both the incidence and chronicity of ITP, and established data regarding implicit bias in medical decision making, this clearly deserves further study 22 …”

Section: Discussionmentioning

confidence: 99%

Quality of life is an important indication for second‐line treatment in children with immune thrombocytopenia

Shimano

Neunert

Bussel

et al. 2021

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Background The decision to initiate second‐line treatment in children with immune thrombocytopenia (ITP) is complex and involves many different factors. Methods In this prospective, observational, longitudinal cohort study of 120 children from 21 centers, the factors contributing to the decision to start second‐line treatments for ITP were captured. At study entry, clinicians were given a curated list of 12 potential reasons the patient required a second‐line treatment. Clinicians selected all that applied and ranked the top three reasons. Results Quality of life (QOL) was the most frequently cited reason for starting a second‐line therapy. Clinicians chose it as a reason to treat in 88/120 (73%) patients, as among the top three reasons in 68/120 (57%), and as the top reason in 32/120 (27%). Additional factors ranked as the top reason to start second‐line treatment included severity of bleeding (22/120, 18%), frequency of bleeding (19/120, 16%), and severity of thrombocytopenia (18/120, 15%). Patients for whom QOL (p = .006) or sports participation (p = .02) were ranked reasons were more likely to have chronic ITP, whereas those for whom severity (p = .003) or frequency (p = .005) of bleeding were ranked reasons were more likely to have newly diagnosed or persistent ITP. Parental anxiety, though rarely the primary impetus for treatment, was frequently cited (70/120, 58%) as a contributing factor. Conclusion Perceived QOL is the most frequently selected reason pediatric patients start second‐line therapies for ITP. It is critical that studies of treatments for childhood ITP include assessments of their effects on QOL.

show abstract

“…Die ITP-Inzidenz ist bei Afroamerikaner*innen deutlich niedriger als bei Kaukasier*innen. Bei Afroamerikaner*innen mit Thrombozytopenie sollte deshalb besonders genau geprüft werden, ob es sich wirklich um eine ITP und nicht doch eine andere Form einer Thrombozytopenie handelt [6]. Im asiatisch-pazifischen Raum scheint die ITP genauso häufig zu sein wie in Europa.…”

Section: Epidemiologieunclassified

Expertenreport Immunthrombozytopenie – Aktuelle Diagnostik und Therapie

Matzdorff

Alesci²,

Gebhart

et al. 2022

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences

Cited by 9 publications

References 15 publications

Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland

Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland

Quality of life is an important indication for second‐line treatment in children with immune thrombocytopenia

Expertenreport Immunthrombozytopenie – Aktuelle Diagnostik und Therapie

Contact Info

Product

Resources

About